2010 Fiscal Year Final Research Report
The elucidation of an ethnic difference of lung cancer and the development of a new therapy
| Project/Area Number |
20590924
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
ISHIKAWA Nobuhisa Hiroshima University, 大学院・医歯薬学総合研究科, 助教 (90423368)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
NOBUOKI Kohno 広島大学, 大学院・医歯薬総合研究科, 教授 (80215194)
HATTORI Noboru 広島大学, 大学院・医歯薬総合研究科, 准教授 (00283169)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 肺癌 / 肺線維症 / 慢性閉塞性肺疾患 / ムチン / バイオマーカー / 人種差 |
|---|
| Research Abstract |
The circulating levels of KL-6 and SP-D in European were higher than those in Japanese control subjects suggesting that the cut-off level for these biomarkers in the European are probably higher than in the Japanese population.We demonstrated that pretreatment serum levels of KL-6 can serve as an independent prognostic factor for NSCLC patients treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI) in a large multi-institutional setting. We also showed that among NSCLC patients with wild-type EGFR, progression free survival (PFS) was significantly shorter in patients with high serum KL-6 levels than in patients with normal serum KL-6 levels.
|
Research Products
(28 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Usefulness of monitoring the circulating Krebs von den Lungen-6 levels to predict the clinical outcome of patients with advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.2008
Author(s)
Ishikawa N, Hattori N, Yokoyama A, Tanaka S, Nishino R, Yoshioka K, Ohshimo S, Fujitaka K, Ohnishi H, Hamada H, Arihiro K, Kohno N.
-
Journal Title
Int J Cancer 122
Pages: 2612-2620
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Krebs von den Lungen-6 (KL-6) is a Prognostic Biomarker for Non-Small Cell Lung Cancer.
Author(s)
Tanaka S, Hattori N, Ishikawa N, Shoda H, Takano A, Nishino R, Okada M, Arihiro K, Inai K, Hamada H, Yokoyama A, Kohno N.
-
Journal Title
Peer Reviewed
-
[Journal Article] Erlotinib efficacy and cerebrospinal fluid concentration in lung adenocarcinoma patients developing leptomeningeal metastases during gefitinib therapy.
Author(s)
Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N.
-
Journal Title
Cancer Chemoth Pharm (印刷中)
Peer Reviewed
-
-
-
-
-
-
-
-
